Introduction Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia. The impact of AF on quality of life (QoL) is significant, and much has related to the achieved resting ventricular rate (VR). Strategies to control VR can improve QoL in AF patients. However, the ideal VR target remains unclear. Therefore, we aimed to identify the ideal VR target by comparing the QoL of AF patients with different VR cut-off means from the 24-hour Holter (Holter). Methods A cross-sectional study was conducted on AF patients in the international normalized ratio (INR) clinic at Hospital Universiti Sains Malaysia. Patients were fixed with a Holter monitor while QoL was measured using the SF-36v2 Health Survey. Patients were repeatedly divided into mean 24-hour Holter VR above and below 60, 70, 80, 90, and 100 beats per minute (bpm). The differences in the total SF-36v2 score and its components were examined. Results A total of 140 patients completed the study. There was a significant difference in physical role, vitality, mental health, mental component summary, and total SF-36v2 scores for VR above and below 90 bpm. The total SF-36v2 score difference was also significant in the covariate analysis, while other VR cut-offs (60, 70, 80, and 100 bpm) did not show significant changes in total SF-36v2 scores. Conclusion Significant differences were observed in the QoL scores among AF patients, with a cut-off VR of 90 bpm favoring patients with the higher rate. Hence, higher VR is better in terms of QoL among stable AF patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162884PMC
http://dx.doi.org/10.7759/cureus.37181DOI Listing

Publication Analysis

Top Keywords

total sf-36v2
16
24-hour holter
12
patients
10
ventricular rate
8
quality life
8
atrial fibrillation
8
qol patients
8
ideal target
8
patients cut-off
8
sf-36v2 score
8

Similar Publications

Article Synopsis
  • The SURMOUNT-1 trial studied the effects of tirzepatide, a medication targeting obesity, on the health-related quality of life (HRQoL) of participants.
  • Participants reported significant improvements in physical function, psychosocial well-being, and overall health, with greater benefits observed in those achieving higher weight reductions.
  • Results highlighted that individuals with initial physical or psychosocial limitations experienced even more pronounced improvements in their health-related quality of life.
View Article and Find Full Text PDF

Purpose: This study quantified the burdens of bipolar I disorder (BP-I) by examining patient characteristics, health-related quality of life (HRQoL), health care resource utilization (HCRU), and costs of patients with versus without BP-I. Additionally, these outcomes were assessed across BP-I severity levels.

Methods: A retrospective, cross-sectional analysis of the 2020 National Health and Wellness Survey was conducted.

View Article and Find Full Text PDF
Article Synopsis
  • Degenerative cervical myelopathy (DCM) affects about 2% of adults, and there is a lack of standardized outcomes in clinical research, leading to inconsistencies in study results; creating a standardized minimum data set could enhance comparability.* -
  • The study used a modified Delphi method to develop a core outcome set (COS), core data elements (CDEs), and a core measurement set (CMS) for DCM research, with input from an international stakeholder group.* -
  • In total, 28 outcomes were identified across 6 key domains, culminating in a structured data set that can be utilized in future clinical trials to ensure consistency and improve measurement accuracy in DCM research.*
View Article and Find Full Text PDF

Background And Purpose: HER-MES was the first head-to-head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER-MES study evaluated the effect of erenumab versus topiramate on patient-reported outcomes at week 24.

Methods: Adult patients with episodic or chronic migraine (n = 777) were randomized (1:1) to monthly subcutaneous erenumab (n = 389) or daily oral topiramate (n = 388).

View Article and Find Full Text PDF

Background: Patient-reported outcomes measurement information system (PROMIS) measures can be used to measure patient-reported outcomes. PROMIS measures, including computer adaptive tests (CATs) and short forms, have demonstrated the ability to adequately assess outcomes in patients with hemophilia. It is, however, unclear if PROMIS measures are suitable for patients with von Willebrand disease (VWD), inherited platelet function disorders (IPFDs), and rare bleeding disorders (RBDs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!